Impact of anemia in patients with head and neck cancer treated with radiation therapy

Current Treatment Options in Oncology

Volumn 6, Issue 1, 2005, Pages 31-45

  Hu, Kenneth ^a   Harrison, Louis B ^b  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; ETANIDAZOLE; FERROUS SULFATE; FLUOROURACIL; HEMOGLOBIN; IRON; MISONIDAZOLE; MITOMYCIN; MITOMYCIN C; NIMORAZOLE; NITROIMIDAZOLE; OXYGEN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ADJUVANT CHEMOTHERAPY; ANEMIA; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CORRELATION COEFFICIENT; DISEASE CONTROL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; HEAD AND NECK CANCER; HEMOGLOBIN DETERMINATION; HUMAN; HYPOXIA; INCIDENCE; IRON THERAPY; LARYNX CANCER; MULTIMODALITY CANCER THERAPY; OPEN STUDY; PILOT STUDY; PREDICTION; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE; RADIOSENSITIVITY; RANDOMIZATION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 13544255736     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-005-0011-4     Document Type: Review

References (68)

1. Mundt AJ, Connell PP, Campbell T, et al.: Race and clinical outcome in patients with carcinoma of the uterine cervix treated with radiation therapy. Gynecol Oncol 1998, 71:151-158.
2. Takeshi K, Katsuyuki K, Yoshiaki T, et al.: Definitive radiotherapy combined with high-dose-rate brachytherapy for stage III carcinoma of the uterine cervix: retrospective analysis of prognostic factors concerning patient characteristics and treatment parameters. Int J Radiat Oncol Biol Phys 1998, 41:319-327.
3. Forastiere AA, Berkey B, Maor M, et al.: Phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone. Intergroup trial R91-11. Proc Am Soc Clin Oncol 2001, 20: a.
4. Teicher BA: Physiologic mechanisms of therapeutic resistance: blood flow and hypoxia. Hematol Oncol Clin North Am 1995, 9:475-506.
5. Harrison LB, Shasha D, Homel P: Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment. Oncology 2002, 63(Suppl 2):11-18.
6. Hu K, Nwokeoi E, Culliney B, et al.: Delayed accelerated hyperfractionated radiation with concurrent cis-platinum without induction chemotherapy for organ preservation therapy of stage III/IV head and neck cancer. Radiother Oncol 2002, 64(Suppl 1):S251.
7. Hu K, Sachoeva G, Culliney B, et al.: Accelerated fractionated radiation by concomitant boost (AFX-CB) with concurrent cis-platinum for advanced nasopharyngeal cancer. Paper presented at the 85th Annual Meeting of the American Radium Society. Chicago, IL; 2003.
8. Lee DJ, Cosmatos D, Marcial VA, et al.: Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 1995, 32:567-576.
9. Fazekas JT, Scott C, Marcial V, et al.: The role of hemoglobin concentration in the outcome of misonidazole-sensitized radiotherapy of head and neck cancers: based on RTOG trial #79-15. Int J Radiat Oncol Biol Phys 1989, 17:1177-1181.
10. Overgaard J, Hansen HS, Overgaard M, et al.: A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998, 46:135-146.
11. Dubray B, Mosseri V, Brunin F, et al.: Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 1996, 201:553-558.
12. Al-Sarraf M, LeBlanc M, Giri PG, et al.: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998, 16:1310-1317.
13. Calais G, Alfonsi M, Bordet E, et al.: Radiation (RT) alone versus RT with concomitant chemotherapy (CT) in stages III and IV oropharynx carcinoma: final results of the 94-01 GORTEC randomized study. Int J Radiat Oncol Biol Phys 2001, 51(Suppl 1 ):1.
14. Munro AJ: An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995, 71:83-91.
15. El-Sayed S, Nelson N: Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: a meta-analysis of prospective and randomized trials. J Clin Oncol 1996, 14:838-847.
16. Bourhis J, Eschwege F: Radiotherapy-chemotherapy combinations in head and neck squamous cell carcinoma: overview of randomized trials. Anticancer Res 1996, 16:2397-2402.
17. Rosen FR, Haraf DJ, Kies MS, et al.: Multicenter randomized phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res 2003, 9:1689-1697.
18. Stadler P, Feldmann HJ, Creighton C, et al.: Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer. Radiother Oncol 1998, 48:157-164.
19. Hockel M, et al.: Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol 1993, 51:141-149.
20. Becker A, Hansgen G, Richter C, Dunst J: Oxygenation status of squamous cell carcinoma of the head and neck: comparison of primary tumors, their neck node metastases and normal tissue. Strahlenther Onkol 1998, 174:484-486.
21. Brizel DM, Dodge RK, Clough RW, Dewhirst MW: Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999, 53:113-117.
22. Nordsmark M, Overgaard J: A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000, 57:39-43.
23. Hirst DG: What is the importance of anaemia in radiotherapy? The value of animal studies. Radiother Oncol 1991, 20(Suppl 1):29-33.
24. Warde P, O'Sullivan B, Bristow RG, et al.: T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 1998, 41:347-353.
25. Hirst DG: Anemia: a problem or an opportunity in radiotherapy? Int J Radiat Oncol Biol Phys 1986, 12: 009-2017.
26. Rockwell S, Keyes SR, Sartorelli AC: Modulation of the antineoplastic efficacy of mitomycin C by dicoumarol in vivo. Cancer Chemother Pharmacol 1989, 24:349-353.
27. Overgaard J, Horsman MR: Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996, 6:10-21.
28. Stadler P, Becker A, Feldmann HJ, et al.: Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999, 44:749-754.
29. Overgaard J: Sensitization of hypoxic tumour cells: clinical experience. Int J Radiat Biol 1989, 56:801-811.
30. Bush RS, Jenkin RD, Allt WE, et al.: Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl 1978, 37:302-306.
31. Bush RS: The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 1986, 12:2047-2050.
32. Harrison LB, Chadha M, Hill RJ, et al.: Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002, 7:492-508.
33. Fein DA, Lee WR, Hanlon AL, et al.: Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995, 13: 077-2083.
34. van Acht MJ, Hermans J, Boks DE, Leer JW: The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma. Radiother Oncol 1992, 23:229-235.
35. Grant DG, Hussain A, Hurman D: Pre-treatment anaemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy. J Laryngol Otol 1999, 113:829-833.
36. Blitzer P, Wang C, Suit H: Blood pressure and hemoglobin concentration: multivariate analysis of local control after irradiation for head and neck cancer. Int J Radiat Oncol Biol Phys 1984, 10(Suppl 2):98.
37. Haddad R, Suntharalingam M, Chen T, et al.: Pretreatment hemoglobin is associated with response to chemoradiation therapy (CRT) in patients with advanced unresectable squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 2001, 19:417a.
38. Overgaard J, Hansen HS, Andersen AP, et al.: Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 1989, 16:1065-1068.
39. Skladowski K, Tarnawski R, Maciejewski B, et al.: Clinical radiobiology of glottic T1 squamous cell carcinoma. Int J Radiat Oncol Biol Phys 1999, 43:101-106.
40. Tarnawski R, Skladowski K, Maciejewski B: Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglottic larynx. Int J Radiat Oncol Biol Phys 1997, 38:1007-1011.
41. Canaday DJ, Regine WF, Mohiuddin, et al.: Significance of pretreatment hemoglobin level in patients with T1 glottic cancer. Radiat Oncol Investig 1999, 7:42-48.
42. Tucker J, Hixson W, Kim R: Pretreatment hemoglobin in early stage glottic cancer: red flag or red herring? Int J Oncol Biol Phys Proc 1996, 36:336.
43. Sakata K, Aoki Y, Karasawa K, et al.: Radiation therapy in early glottic carcinoma: uni-and multivariate analysis of prognostic factors affecting local control. Int J Radiat Oncol Biol Phys 1994, 30:1059-1064.
44. Lutterbach J, Guttenberger R: Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx. Int J Radiat Oncol Biol Phys 2000, 48: 345-1350.
45. Degner FL, Sutherland RM: Mathematical modelling of oxygen supply and oxygenation in tumor tissues: prognostic, therapeutic, and experimental implications. Int J Radiat Oncol Biol Phys 1988, 15:391-397.
46. Evans SM, Jenkins WT, Shapiro M, Koch CJ: Evaluation of the concept of "hypoxic fraction" as a descriptor of tumor oxygenation status. Adv Exp Med Biol 1997, 411:215-225.
47. Girinski T, Pejovic-Lenfant MH, Bourhis J, et al.: Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 1989, 16:37-42.
48. Surgenor DM, Wallace EL, Hao SH, Chapman RH: Collection and transfusion of blood in the United States, 1982-1988. N Engl J Med 1990, 322:1646-1651.
49. Lavey RS, Dempsey WH: Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 1993, 27:1147-1152.
50. Pedersen D, Sogaard H, Overgaard J: Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone. Acta Oncol 1995, 34:787-795.
51. Henry DH: Changing patterns of care in the management of anemia. Semin Oncol 1992, 19(Suppl 8):3-7.
52. Littlewood TJ, Bajetta E, Nortier JW, et al.: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001, 19:2865-2874.
53. Quirt I, Robeson C, Lau CY, et al.: Epoetin alpha therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001, 19:4126-4134.
54. Gabrilove J, Cleeland CS, Livingston RB, et al.: Clinical evaluation of once-weekly dosing of epoetin alpha in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001, 19: 875-2882.
55. Cleeland C, Demetti G, Glaspy J, et al.: Identifying hemoglobin level for optimal quality of life: results of an incremental analysis. Proc Am Soc Clin Oncol 1999, 18:574a.
56. Cella D, Dobrez D, Glaspy J: Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003, 14: 11-519.
57. Henke M, Guttenberger R, Barke A, et al.: Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother Oncol 1999, 50:185-190.
58. Thews O, Koenig R, Kelleher DK, et al.: Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 1998, 78:752-756.
59. Stuben G, Pottgen C, Knuhmann K, et al.: Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 2003, 55:1358-1362.
60. Sweeney PJ, Nicolae D, Ignacio L, et al.: Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial. Br J Cancer 1998, 77:1996-2002.
61. Dusenbery K, McGuire WA, Holt PJ, et al.: Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 1994, 29:1079-1084.
62. Shasha D, George MJ, Harrison LB: Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003, 98:1072-1079.
63. Lavey RS: Clinical trial experience using erythropoietin during radiation therapy. Strahlenther Onkol 1998, 174(Suppl 4):24-30.
64. Glaser C, Millesi W, Gossweiner S, et al.: rHuEPO supply increases efficacy of neoadjuvant radiochemotherapy in patients with oral squamous cell carcinoma. Proc Am Soc Clin Oncol 1998, 17:397a.
65. Glaser C, Millesi W, Wanschitz F, et al.: rHuEPO treatment increases efficacy of neoadjuvant radiochemotherapy and improves cancer free survival of patients with oral squamous cell carcinoma: a 17-month follow-up. Proc Am Soc Clin Oncol 1999, 18:399a.
66. Glaser CM, Millesi W, Kornek GV, et al.: Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001, 50:705-715.
67. Machtay M: A randomized phase III trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiotherapy for carcinoma of the head and neck. RTOG 99-03. Radiat Ther Oncol Group 2000.
68. Henke M, Laszig R, Rube C, et al.: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362:1255-1260.